Role of gene polymorphisms in vitamin D metabolism and in multiple sclerosis

Aylin Elkama and Bensu Karahalil

Gazi University, Faculty of Pharmacy, Department of Toxicology, Ankara, Turkey

[Received in November 2017; Similarity Check in November 2017; Accepted in March 2018]

Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS) resulting in neurological impairment and disability. There is evidence that adequate vitamin D levels may lower the risk of MS development. The aetiology of MS is complex and involves both genetic and environmental factors. In fact, not one but several genes are believed to lead to the disease. As for environmental factors, one of the most important risk factors is vitamin D deficiency, which, in turn, is closely related to gene polymorphisms that play a role in vitamin D metabolism and regulation. However, information about these gene polymorphisms is quite contradictory. The aim of this review is to discuss the association between some of the vitamin D-related gene variants and MS.

KEY WORDS: cytochrome P; HLA-DRB1; vitamin D receptor

Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune, and demyelinating disease of the central nervous system (CNS). It is estimated that 2.1 million people have MS worldwide (1). MS is the most common neurodegenerative disorder of Caucasian 25 to 35-year-old adults. Women are affected three times more often than men (2). It starts as an autoimmune response to myelin proteins and other unidentified antigens that results in the demyelination and dense astrogliosis in the white matter of the brain (3). It is widely believed that the culprits for early demyelination in MS are T-cell-mediated autoimmune responses and oligodendrocyte apoptosis (4). Lymphocytes infiltrate the CNS and damage myelin and axons. The resulting neurodegeneration then leads to musculoskeletal dysfunction, muscle weakness and pain, visual problems, severe disability, and eventually death (5).

Low sun exposure is linked to low levels of vitamin D, and the primary source of vitamin D is ultraviolet B (UVB) light from the sun with a wavelength between 290 and 315 nm, particularly in the summer (6).

The biologically active form of vitamin D is 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), which is produced in several steps. A large proportion comes from the UVB-induced biotransformation of 7-dehydrocholesterol to vitamin D3, followed by two hydroxylation reactions. The first, the formation of vitamin D metabolite 25-hydroxyvitamin D3 25(OH)D3 occurs in the liver. The second occurs in the kidneys, where the active metabolite, 1,25(OH)2D3, is formed, enters the cell, and binds to the vitamin D receptor (VDR) (6, 8).

Most of the biological functions of vitamin D3 are mediated through VDR (6, 8). Monocytes, macrophages, dendritic cells, activated T and B cells are known to carry VDR on their surfaces. The major role of 1,25(OH)2D3 is to modulate immune response. Acting as a steroid hormone, vitamin D controls infections by enhancing the phagocytic and antibacterial activities of immune cells. Furthermore, vitamin D inhibits the production of pro-inflammatory cytokines (which play an important role in the development of many chronic autoimmune diseases) by stimulating regulatory T-cells and reducing T-cell proliferation. Several studies have shown that vitamin D helps the regulation of the immune system (9, 10). It is also essential for bone and calcium homeostasis (5).

Vitamin D deficiency, in turn, is believed to be associated with bone fractures, cognitive disorders, dementia, cancer, stroke, and neurodegenerative diseases, including MS (6, 11). The best indicator of vitamin D status is the serum 25(OH)D level. Levels below 30 nmol L⁻¹...
(12 ng mL\(^{-1}\)) suggest vitamin D deficiency and 30-50 nmol L\(^{-1}\) (12-20 ng mL\(^{-1}\)) vitamin D insufficiency. Levels between 50 and 75 nmol L\(^{-1}\) (20-30 ng mL\(^{-1}\)) are considered normal (12).

However, even though epidemiological studies demonstrate low serum vitamin D levels and high rates of bone fractures in MS patients (5, 13), what stands behind this association with MS is still not clear. Some researchers suggest that vitamin D deficiency increases the risk of MS by putting the immune system in a more pro-inflammatory state (6).

Case-control studies have shown that vitamin D levels are significantly lower in people with MS than in healthy controls. In one of those studies (14), 61 % of MS patients had vitamin D insufficiency. These findings raise the question of whether low vitamin D levels increase the risk of MS or is it vice versa, that MS decreases vitamin D levels. Is it, perhaps, that MS symptoms, which are exacerbated by heat, may lead to sun avoidance and result in lower vitamin D levels? Or is it that vitamin D deficiency/insufficiency triggers MS (7)?

One argument against the first proposal is that gene variances in vitamin D metabolism can substantially affect serum vitamin D levels, despite sufficient UVB exposure. This is particularly true of the gene polymorphisms of drug metabolising enzymes and receptors. For example, single nucleotide polymorphisms (SNPs) of metabolising enzymes and VDR may modify how these proteins and the immune system work. In other words, polymorphisms of the genes involved in vitamin D regulation may affect susceptibility to MS development (6). And there are many gene polymorphisms of many immune receptors and drug carrier enzymes that contribute to MS.

The aim of this review was to discuss the most studied VDR and CYP450 gene polymorphisms and see how they are related to the development of MS in order to understand the functional consequences of these variations and find possible applications in risk assessment of the disease.

**POLYMORPHISMS OF VITAMIN D METABOLISM GENES**

**VDR gene polymorphisms**

VDR is an intracellular receptor that belongs to the steroid/thyroid nuclear receptor family and is found in various tissues, including brain, immune cells, and peripheral blood monocytes. The VDR gene is located on 12q13.1, consists of 9 exons and 8 introns, and has numerous allelic variants (11). 11,25(OH)\(_2\)D\(_3\) interacts with the VDR and then binds to the retinoid X receptor (RXR) to form a heterodimer complex. This heterodimer complex binds to the VDR response elements (VDRE) in the promoter region of the target genes in the nucleus. However, in the absence of 1,25(OH)\(_2\)D\(_3\), VDR shuttles between the nucleus and cytoplasm instead of activating and translocating into the nucleus. Moreover, the heterodimer complex is not stable enough to bind to DNA, which results in repression of target gene transcription (15).

VDR gene variants can severely affect gene activation and disturb vitamin D and calcium metabolism, thereby increasing the risk of autoimmune diseases such as MS (1). Considering that recent research points to VDR SNPs in the development of MS, researchers are hoping to clarify the relationship between vitamin D and MS (15). Among over 30 VDR SNPs (16) the most studied are FokI (rs10735810), BsmI (rs1544410), TaqI (rs731236), and ApaI (rs7975232). However, reports about the association between these four gene polymorphisms and MS risk are controversial (16-20).

BsmI (A/G substitution), TaqI (T/C substitution), and ApaI (G/T substitution) are located at the 3’ end of the VDR gene and do not result in any structural change of the VDR protein, but there is evidence that these polymorphisms may affect VDR function through altered activation of VDR expression (1, 4, 15, 21). However, only the FokI polymorphism has been associated with variations in vitamin D levels in MS patients (8, 15, 17, 22). The FokI polymorphism is located in the translation initiation site in exon 2 of the VDR gene and results in two different transition initiation sites in the VDR. T to C substitution in the first translation initiation codon ATG leads to long (ff) and short (FF) variants of the VDR protein (8).

**FokI**

The missense SNP of FokI does not interfere with DNA binding, ligand binding, and heterodimer formation with the RXR. However, the F allele has higher transcriptional activity (1). It is reported that the f allele of FokI has a lower frequency in Africans than in European Caucasians and Asians (23). A case-control study (22) from the Netherlands with 212 MS patients and 289 healthy controls showed that the F (shorter) allele of FokI corresponded to significantly higher levels of 1,25(OH)\(_2\)D\(_3\) and significantly lower levels of 25(OH)\(_3\)D\(_3\) in the serum of MS patients compared to the f (longer) allele (p=0.034). Likewise, a Sicilian study with 104 MS patients and 75 healthy controls determined low serum 25(OH)\(_2\)D\(_3\) levels in MS patients with the FF and the Ff genotypes compared to the MS patients with the ff genotype (8).

A study with north European Caucasians pointed to a lower expression of the ff genotype in MS patients (24). Beside the differences in transcriptional activity of the FokI variant, this polymorphism may also determine the severity of MS (15). In another study (25), in a total of 512 northern European Caucasians the f allele of FokI was associated with a milder disability after the onset of MS between individuals with the Expanded Disability Status Score (EDSS) <6 and those with EDSS ≥6. In another words, the f allele was associated with reduced risk of disability. These data indicate that the VDR FokI polymorphism has...
important consequences for vitamin D metabolism in both MS and healthy control subjects. However, there are several studies that did not find any significant link between the VDR polymorphism and vitamin D levels (26) or the risk of MS (2, 16, 17, 272, 16, 18, 24). An American study (17) found an association between the shorter, F allele (determined in 214 women with MS) and increased transcripational activity, but no association between MS and vitamin D intake among these women (OR=0.93, 95% CI=0.78-1.09). However, the study established a significantly lower risk of MS risk in women with the ff genotype who were taking vitamin D supplementation (RR=0.21, 95% CI=0.06-0.78, p=0.026) (17). Several other studies found no association between the VDR FokI polymorphism and risk of MS, such as those conducted in Canada (28), Australia (27), Iran (1, 11), and Spain (29).

**BsmI**

There are several studies showing a strong association between the VDR BsmI polymorphism and MS risk (1, 11, 29). While in the Japanese population A allele is more common, a significantly higher frequency of the homozygote G allele (GG) was found in 77 MS patients compared to 95 healthy controls (OR=2.38, 95% CI=1.11-5.11, p=0.0048) (18). In contrast, a Slovak case-control study (30) did not observe any role of BsmI allelic variants in MS susceptibility among 270 MS patients (58.3 % G allele vs 41.7 % A allele) and 303 healthy controls (57.6 % G allele vs 42.4 % A allele). However, with a robust analysis they found a protective effect of the AA genotype against MS development when compared to the G allele (OR=0.59, 95% CI=0.39-0.9, p=0.014) (30). This protective effect is supported by the functional impact of the G allele of BsmI on the VDR gene expression. Another study reported that the G allele of BsmI decreases VDR mRNA expression (31). Therefore, the absence of the G allele or the presence of the AA genotype may result in normal or increased expression of VDR. A change in VDR expression may improve receptor function and signalling and thus enhance the protective effects of vitamin D against MS (30).

An Iranian study with 113 MS patients and 112 healthy controls confirmed the protective effect of the AA genotype of BsmI against MS development, and also found a positive association between the G allele and MS (OR=1.7, 95% CI=1.1-2.5, p=0.012) (11). Another Iranian study (1) confirmed the association between BsmI polymorphism and MS risk. Interestingly the AA genotype frequency in that study was higher in the 160 MS patients than in the 150 healthy controls (OR=2.52, 95% CI=1.31-4.83, p=0.005; OR=1.88, 95% CI=1.35-2.6, p=0.0002, respectively).

In a sample population from northwestern Greece (32), no direct association was established between BsmI polymorphism and MS risk or bone mineral density (BMD). However, the study reported that lower BMD and increased frequency of osteoporosis in MS patients was associated with vitamin D insufficiency. Yet, another Greek study (5) reported an association between BsmI polymorphism and bone loss in patients with MS.

**TaqI**

TaqI is another VDR gene polymorphism studied for association with MS. In addition to reports of the strong correlation between TaqI and 25(OH)2D3 levels (22), several studies have corroborated its role in MS development. A Tunisian study (4) showed that the frequency of the T allele of TaqI was significantly lower in 60 MS patients than in 114 healthy controls, which suggests that it might protect against MS development (OR=0.52, 95% CI=0.3-0.9, p=0.012). In contrast, the C allele of TaqI appeared to predispose for MS. However, these findings have not been confirmed by other Caucasian Spanish (18), southern Spanish (33), Greek (32), Canadian (28), Slovak (30), and Dutch (34) studies. They all show no differences in allelic variant frequencies between MS patients and healthy controls. Huang and Xie (16) believe that this disagreement is owed to ethnicity-specific genetic variations between the studied populations. Indeed, different frequencies of the T allele of TaqI have been reported for different ethnic groups, as follows: 60 % in the American population (17), 63 % in the Greek population (32), 65.5 % in the Caucasian Spanish population (29), and 82 % in the Tunisian population (4). The C allele of TaqI has been reported to have a lower frequency in Asians than in Africans and European Caucasians (23). Interestingly, an Australian Caucasian study (13) with 104 MS patients and 104 healthy controls, found that the otherwise rarer T allele (allele which is cut by TaqI enzyme) was more common in MS patients than in healthy controls. The risk of MS associated with it was at least twice as high as that in non-carriers (OR=2.35, 95% CI=1.29-4.27, p=0.0048). Furthermore, the T allele of TaqI involved a three times higher risk of MS. A higher frequency of the T allele of TaqI was also detected in 560 MS cases from United Kingdom and Australia in comparison to 480 healthy controls (2).

On the other hand, TaqI and BsmI genotype distribution was significantly different in 50 MS patients than 50 healthy controls and was associated with MS risk in the Kuwaiti population (35).

**ApaI**

In general population the T allele of ApaI has a higher frequency in Asians and European Caucasians than in Africans (23). Findings about the association of ApaI polymorphisms with MS risk are also inconclusive. In a study of a Tunisian population (4), ApaI was not associated with MS risk; neither the allele nor the genotype frequency distribution significantly differed between MS patients and healthy controls (p>0.05). A study in Slovak (30) and Kuwaiti population (35) showed similar findings. The latter
study also found no association between *ApaI* and vitamin D levels.

In contrast, studies in Australian Caucasian (13) and Japanese populations (36) found a positive association between *ApaI* and the development of MS. In the Australian Caucasian study, the *T* allele of *ApaI* was significantly associated with MS (*p*=0.05) and there was a strong linkage disequilibrium between *Taql* and *ApaI* variants (13). The Japanese study showed higher frequency of the *T* allele of *ApaI* and the *TT* genotype in 77 MS patients compared to 95 healthy controls (*p*=0.032 and *p*=0.007, respectively) (36).

**Cdx-2**

A few studies have also investigated the association between *Cdx-2* polymorphism, another SNP in the *VDR* gene, and MS. This polymorphism causes an *A* to *G* substitution in the 5' UTR region of the gene and affects the function of the CDX2 transcription factor. *Cdx-2* is primarily expressed in the gut, and autoimmune diseases, including MS, are assumed to be related with gut immunity. However, the association between MS development and reduced CDX activity in the gut is uncertain (27).

An Australian study (27) with 113 MS patients and 234 healthy controls observed an increased MS risk in *G* allele carriers exposed to sunlight for less than one hour a day (OR=1.87; 95 % CI=1.07-3.28). Compared to the *A* allele, the *G* allele of *Cdx-2* was associated with a 70 % reduction in transcriptional activity of the *VDR* gene promoter. On the other hand, the study did not find any significant association between MS risk and the *GG* genotype versus the *AA* genotype.

In contrast, a French study (19) conducted in MS patients and age- and sex-matched controls found no significant association between *Cdx-2* and MS, but it did establish a threefold increase in MS risk in the carriers of maternal *G* allele and paternal *A* allele (OR=3.13; 95 % CI=1.3-7.7). A US Caucasian study also found no significant association between MS and *Cdx-2* polymorphism (RR=0.97; 95 % CI=0.79-1.21) (17).

A study in middle-aged and elderly Chinese women (37), however, found an association between *Cdx-2* polymorphism and serum 25(OH)D levels and BMD.

**Meta-analysis of the VDR gene polymorphisms**

Meta-analysis provides more robust data than individual studies by compiling data from many studies to produce a large sample size. A recent meta-analysis (38) that included a total of 3300 MS patients and 3194 controls from 13 case-control studies evaluated the four *VDR* genes, *ApaI*, *Taql*, *BsmI*, and *FokI* and found that the homozygote *AA* genotype of *ApaI* and the *FF* genotype of *FokI* were significant risk factors for MS development, but found no such association for the *BsmI* and *Taql* polymorphisms. This meta-analysis covers a wide range of ethnic groups, including Asians (from Japan), European Caucasians (from UK, Italy, Greece, and Spain), Australians (from Tasmania), Australian Caucasians (from Queensland), Netherlands Caucasians, and Caucasian Americans (from Boston, USA). The authors reported that the data were moderately heterogeneous due to ethnic differences, study periods, and geographical latitude.

Another meta-analysis (16), which covered the same studies save for two Spanish Caucasian studies, suggested that these four *VDR* gene polymorphisms were not associated with the risk of MS. The main reason for this result was the heterogeneity and inconsistencies between the studies, such as diagnosis of the disease, ethnic and geographical factors, sex, and different genotyping methods.

**Interaction between HLA-DRB1 and the VDR gene polymorphisms**

Environmental factors alone are not sufficient to explain why African American, Asian, or North American indigenous populations are more resistant to MS than Europeans, which, in turn, points to genetics (39). It is not easy to determine MS susceptibility in terms of association with one or two gene polymorphisms, since MS is a complex, polygenic heritable disorder.

However, Fernandez de Abreu et al. (19) have singled out *HLA-DRB1* locus as the main susceptibility region and have provided a robust association between the risk of MS and *HLA-DRB1* polymorphism. They have identified VDRE in the promoter region of *HLA-DRB1* as the binding target for VDR. Cox et al. (2) suggest that *HLA-DRB1* expression may be altered by 1,25(OH)2D3, the active form of vitamin D. In fact, they claim that *HLA-DRB1*1501 carries the highest genetic risk of MS development.

There is growing evidence of a direct interaction between *HLA-DRB1* and vitamin D as the main environmental contributor to MS. Studies (39, 40) suggest that the expression of *HLA-DRB1* in the thymus is affected by vitamin D deficiency in childhood, and that the underexpression of the *HLA-DRB1*1501 allele in the thymus might increase the risk of autoimmune diseases such as MS.

The MS-associated *HLA-DRB1*1501 allele is not distributed equally among ethnicities; it is high in Caucasians and low in Africans and Asians. Moreover, it is more common in women with MS (39). This finding that the association between the *HLA-DRB1*1501 allele and MS is specific for women has also been supported by Irizar et al. (33).

There are several other studies investigating the role of the *HLA-DRB1*1501 allele alone and in combination with other *VDR* gene polymorphisms in MS susceptibility (27, 33, 36, 20). A study in Australian Caucasians (27) showed a correlation between *Cdx-2* and the *HLA-DRB1*1501 allele, with the *HLA-DR15* locus having the strongest
association with MS susceptibility (OR=3.91, 95% CI=2.34-6.56).

A study in a Japanese population (36) found that the combination of the T allele of Apal and HLA-DRB1*1501 allele increased the risk of MS (OR=2.069). They also suggested that the HLA and the VDR BsmI/Apal alleles combined may have a role in the development of the disease.

Another study of 1360 MS patients and 1677 healthy controls in Canada showed that HLA-DRB1*15 carriers with the longer isoform T allele of FokI ran the higher risk of MS (p=0.034) (20).

CYP27B1 gene polymorphism

Cytochrome P450 CYP27B1 metabolising enzyme has also been investigated in MS susceptibility due to its importance in vitamin D3 activation. This enzyme regulates the level of biologically active vitamin D and plays an important role in calcium homeostasis (41). It codes for the 25-hydroxy-vitamin D-1 alpha hydroxylase enzyme, which hydroxylates the inactive form 25(OH)D3 into its active form 1-25(OH)2D3. Therefore, its gene polymorphisms may alter vitamin D metabolism and, consequently, its regulatory role. Recently, the Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZ gene) reported a strong association between the CYP27B1 gene and MS (p=5.4x10^-11) (42). This association was confirmed by Sundqvist et al. (43) in a Swedish population (2158 MS patients and 1759 healthy controls).

In contrast, Simon et al. (17) found no such association. Instead, they observed that the combination of dietary vitamin D supplementation and the VDR FokI ff genotype could reduce the risk of MS (p=0.02).

In summary, among the VDR variants, the FokI f, BsmI A, TaqI T, and Apal G alleles have been singled out as protective against MS in most but not all studies, mostly due to ethnic differences. Furthermore, there are environmental factors to consider, along with the genetic ones. The HLA-DRB1*1501 allele is the most likely variant to be involved in MS, and its interaction with other genes involved in vitamin D metabolism has drawn scientific attention. CYP450 gene polymorphisms have received less attention in this context and need further research.

CONCLUSION

So far, epidemiological studies have reported conflicting findings about gene polymorphisms involved in vitamin D metabolism and their association with MS. It is still unclear which and how many genes are involved in the development of MS, but it is pretty clear that research should focus on the ones that lead to vitamin D insufficiency. However, this does not complete the picture. In order to elucidate the mechanisms of MS development, other parameters participating in vitamin D metabolisms should be taken into account, such as co-factors, enzyme activities, and epigenetic regulation of genes involved in vitamin D metabolism. Furthermore, MS cannot be explained by any single factor alone, whether it is environmental or genetic. Future large genome-wide studies of gene-gene and gene-environment interactions that include other risk parameters are needed for us to be able to assess the risk of MS.

Conflict of interest

None to declare.

Funding

The authors received no specific grant from public, commercial, or not-for-profit funding agencies.

REFERENCES

34. Arh Hig Rada Toksikol 2018;69:25-31
Uloga genskih polimorfizama u metabolizmu vitamina D i multiploj sklerozi

Multipla skleroza složena je upalna bolest središnjeg živčanog sustava koja dovodi do neuroloških poremećaja i invalidnosti. Prema nekim istraživanjima, rizik od multiple skleroze manji je u osoba s dovoljnim razinama vitamina D. Etiologija bolesti je složena i obuhvaća nasljedne i okolišne čimbenike. Štoviše, vjeruje se da je više gena odgovorno za nastanak bolesti, a od okolišnih se čimbenika najviše izdvaja nedostatak vitamina D, što je opet povezano s genskim polimorfizima koji su važni za regulaciju njegovog metabolizma u tijelu. Dosadašnja saznanja o tim polimorfizima i njihovoj ulozi, međutim, prilično su oprečna. Stoga je namjera ovoga preglednog članka raspraviti o mogućoj povezanosti između pojedinih varijanti gena za metabolizam vitamina D i nastanka multiple skleroze.

KLJUČNE RIJEČI: citokrom P; HLA-DRB1; receptor vitamina D